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Pharmacotherapy review is a structured assessment of medicines, which aims to obtain a partnership 
with patients to achieve drug treatment goals and agreement about drug dosage, as well as when and 
how the drugs should be administered. The objective was to analyze the influence of pharmacotherapy 
review, by scheduling drug administration to improve medication adherence among antihypertensive 
patients. This study was an uncontrolled intervention developed in three distinct stages. The first stage 
included data collection on the profile of patients and their medications, and a preliminary assessment 
of medication adherence. In the second stage, the review report was delivered to patients. In the third 
stage, the results of blood pressure and medication adherence were assessed. The influence of the revision 
was measured through statistical tests (p<0.05). The study included 40 patients with a mean age of 
58.0 (SD:11.3) years; 72.5% were women. Thirty-three (82.5 %) patients required some intervention, 
after when there was a significant increase in the number of daily doses (p=0.039) and drug intakes 
(p=0.025). There was a significant increase in the adherence rate, according to both the Morisky-Green 
test (p<0.001) and self-reported assessment (p=0.004). There was also an improvement in the levels of 
systolic (p<0.001) and diastolic (p=0.002) blood pressure and in the number of patients with controlled 
hypertension (p=0.006). The pharmaceutical service enhanced medication adherence and control of 
systemic blood pressure; however, it increased the complexity of treatment. 
Uniterms: Pharmacotherapy review. Drugs/administration schedule. Hypertension/medication adherence. 
Medication adherence. Pharmaceutical assistance.
A revisão da farmacoterapia é uma avaliação estruturada dos medicamentos com o objetivo de 
proporcionar aos pacientes o alcance dos objetivos terapêuticos por meio da forma adequada de 
administração dos medicamentos. O objetivo foi analisar a influência da revisão da farmacoterapia, 
por meio do aprazamento dos medicamentos, na adesão à medicação e no controle da hipertensão 
arterial sistêmica. Trata-se de um estudo de intervenção não controlado desenvolvido em três momentos 
distintos.  No primeiro, realizou-se a coleta de dados sobre o perfil dos pacientes e de suas medicações e 
a avaliação da adesão; no segundo momento, realizou-se a entrega do relatório da revisão aos pacientes 
e na terceira etapa avaliou-se o resultado da adesão e pressão arterial. A influência da revisão foi medida 
por meio de testes estatísticos (p<0,05). Participaram deste estudo 40 pacientes, com média de idade 
de 58,0 anos (SD:11,3), sendo 72,5% mulheres. Dos pacientes, 33 (82,5%) necessitaram intervenções. 
Após estas se verificou aumento significativo no número de doses (p=0,039) e no número de tomadas 
(p=0,025). Houve aumento significativo no número de aderentes tanto pelo teste de Morisky-Green 
(p<0,001) quanto na avaliação autorreferida (p=0,004). Também, houve melhora nos níveis de pressão 
sistólica (p<0,001) e diastólica (p=0,002) e no número de pacientes com a pressão controlada (p=0,006).  
O serviço farmacêutico desenvolvido promoveu aumento da adesão e do controle da pressão arterial, no 
entanto, aumentou a complexidade do tratamento. 
Unitermos: Revisão da farmacoterapia. Fármacos/esquema de administração. Hipertensão/adesão à 
medicação. Medicação/adesão. Assistência farmacêutica.
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INTRODUCTION
The treatment of hypertension, which is a common 
chronic condition among adults, is generally continuous 
and uses drug combinations, either to treat the disease, 
or to reduce cardiovascular risk factors and manage 
complications. This feature increases the complexity of the 
treatment resulting in low rates of medication adherence 
and control of pressure levels (Trauthman et al., 2014; 
Correr, Soler, Otuki, 2011; SBC, 2010; Ho, Bryson, 
Romsfeld, 2009).
Low adherence to antihypertensive treatment has 
been considered a major barrier to adequate blood pressure 
control (Holt et al., 2010; Ho, Bryson, Romsfeld, 2009), 
and consequently, the treatment becomes ineffective, 
leading to complications (Correr, Soler, Otuki, 2011; Ho, 
Bryson, Romsfeld, 2009; Osterberg, Blaschke, 2005).
The WHO (2003) defines medication adherence 
as a patient’s degree of compliance in relation to what 
was prescribed or oriented by physicians or other health 
care professionals. Adherence is a complex behavioral 
process that is influenced by several factors (Porto et al., 
2014; Luneli et al., 2009; Osterberg, Blaschke, 2005). 
Therefore, several instruments were developed to assess 
this outcome, including the Morisky-Green test (Morisky, 
Green, Levine, 1986).
In this context, the way people follow drug 
instructions is a big challenge, especially when it comes 
to chronic diseases, since it involves, in addition to use 
of various medications, change in behavior and dietary 
habits (Osterberg, Blaschke, 2005). Corroborating this 
information, the WHO (2003) estimates that 50% of 
patients forget to take their medications. In addition, 
surveys conducted in Brazil with hypertensive subjects 
showed that only one third adhered to medication therapy 
(Prado, Kupek, Mion, 2007; Bastos-Barbosa et al., 2012).
Pharmacotherapy review may be defined as a service 
that performs a review of medications used by patients 
in order to control risks and improve outcomes of drug 
therapy, detecting, resolving and preventing drug-related 
problems (Leikola et al., 2012). Thus, this service is a 
structured assessment of medicines, which aims to obtain 
a partnership with patients to achieve drug treatment 
goals and agreement about the dosage, as well as when 
and how the drugs should be administered (together with 
food or after a fast) (Miranda et al., 2012; Geurts et al., 
2012; Holland et al., 2007). In this context, one of the 
important activities undertaken in this process is the drug 
administration schedule. 
The aim of this study was to analyze the influence of 
pharmacotherapy review upon medication adherence and 
hypertension control in patients in a community pharmacy.
METHODS 
Research setting
The research was conducted in a community 
pharmacy in a small town in southern Brazil. The town 
has just over ten thousand inhabitants according to the 
Brazilian Institute of Geography and Statistics (IBGE, 
2010). With regard to healthcare facilities, there were 
five basic health units, linked to the Brazilian National 
Health System, which provided access to medical, nursing, 
dentistry, psychology, speech therapy, nutrition, pharmacy, 
acupuncture and physiotherapy assistance, in addition to 
four community pharmacies. 
People residing in the municipality could have 
free access to medicines in the basic health units and in 
community pharmacies, provided that the patients had 
prescription drugs either standardized by the municipality 
or by the “health is priceless” program (a specific program 
for free distribution of drugs for hypertension, diabetes, 
and asthma) (Brasil, 2015).
The pharmacy in which the study was conducted 
is located downtown, has two pharmacists, in addition 
to the researcher of this study. This pharmacy provides 
clinical services, such as drug dispensing, indication 
of non-prescription medicines for self-care, orientation 
towards health promotion and rational use of medicines, 
among others. The establishment is also starting the 
implementation of pharmacotherapy review as a tool for 
promoting a more efficient and rational use of medicines. 
Study design (type of study)
This is a non-controlled intervention study.
Population and sample
Patients were eligible for this study if they 
were diagnosed with hypertension and were taking 
antihypertensive medications for at least 30 days.
The sample size was calculated for a one-
tailed hypothesis test, i.e., the only hypothesis is that 
“the completion of the pharmacotherapy review and 
intervention will enhance adherence to medication.” 
The significance level was set at 5% and the test power 
at 80%; the adherence rate was estimated to be 50% 
(Prado, Kupek, Mion, 2007) prior to the intervention and 
70% after the intervention. With these parameters, the 
minimum sample size was estimated to be 36 subjects, 
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but considering the losses and biases, an addition of 10% 
was made, resulting in a final sample of 40 subjects. The 
participants were selected by convenience sampling from 
patients enrolled in the “health is priceless” program of 
the popular pharmacy.
Data collection instrument and procedure
A structured interview previously tested in a pilot 
study was used to interview the patients. The pilot study 
was conducted with 10% of the sample previously 
calculated. Since no substantial changes were made, the 
data were included in the survey.
The research proposal was presented to the patients, 
who were asked to sign a free informed consent form. Only 
consenting subjects were interviewed.
The research was carried out in three stages 
(Figure 1). In stage 1, the patients were invited to 
participate in the study when they came to the community 
pharmacy; if he or she had no time available to do it, 
a home visit was scheduled to conduct the interview. 
In this first interview, the Morisky-Green test (Ben, 
Neumann, Mengue, 2012; Santa-Helena, Nemes, Neto-
Eluf, 2008) was used to assess medication adherence. 
Participants were asked to grade their personal evaluation 
of adherence on a scale ranging from zero to 10, with 
zero representing minimum medication adherence and 
10 the maximum adherence rate. In addition, personal 
information was collected during the first interview, such 
as name, age, gender, education level, major and secondary 
diseases, medications used, concentration and dosage 
of medications, and if they were prescription drugs. If 
FIGURE 1 - Development of the pharmacotherapy review. 
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prescription drugs were reported, the patients were asked 
to present either the prescription or the card of the National 
Public Health System for verification. They were also 
asked about physical activity, diet and efforts to reduce 
sodium intake.
Patients were asked to describe their daily routine 
for the assessment of drug administration schedules. The 
daily routine description included activities from waking 
up through going to bed, such as meals, medications, 
and nap taking. This information was important to assess 
how the respondents were taking their medications and 
possible interactions with food and other drugs used 
concomitantly. During the interview, blood pressure was 
measured, according to the protocol established by the 
6th Hypertension Guideline (SBC, 2010), using a semi-
automatic arm blood pressure monitor (Visomat® Comfort 
III), certified by the National Institute of Metrology, 
Quality and Technology (INMETRO) for Brazil. The 
choice of the brand followed the recommendations by the 
6th Guideline on Hypertension (SBC, 2010). All blood 
pressure measurements were performed by the researcher, 
and were recorded on a card designed for that purpose, 
which was delivered to the patient during the first meeting.
Based on these data, a thorough literature review 
was conducted on the medications used, emphasizing 
how to use, dosage, interactions with food and other 
drugs. Subsequently, the routine described by the patient 
was jotted down in the review report if no problem was 
encountered. In case there was a problem with the routine, 
an intervention was defined; whenever possible, we tried 
to interfere as little as possible with the patient’s routine.
Stage 2 included a presentation of the review 
report to the patient. The report consisted of a document 
that organized the medications to be taken, the amount, 
schedule and nutritional care. When necessary, pictograms 
were used to facilitate information readability. Figure 
2 presents a model of the review report, which was 
subsequently delivered to the patient together with a 
refrigerator magnet. During this second phase, the review 
suitability was evaluated with the patient or caregiver. 
During this meeting, a second blood pressure measurement 
was performed.
Stage 3 was performed within four to six weeks 
after stage 2. A new interview was held for reassessment 
of medication adherence using the Morisky-Green test 
(Ben, Neumann, Mengue, 2012; Santa-Helena, Nemes, 
Neto-Eluf, 2008), self-assessment, and blood pressure 
measurement. The patients were asked about where 
they had kept the review reports, their perception on the 
intervention and suitability of the pharmacotherapy review 
report.
The data collected during the interviews, the 
problems encountered in the patient’s routine and 
interventions on the pharmacotherapy review for each 
patient were recorded on an instrument developed by the 
researcher for that purpose.
Data organization and analysis
Subjects were considered adherent if they responded 
negatively to all questions of the Morisky-Green test (Ben, 
Neumann, Mengue, 2012; Santa-Helena, Nemes, Neto- 
Eluf, 2008). As for self-assessment, adherent patients were 
those who scored equal to or greater than 8. This score 
was set because patients are considered adherent if they 
comply with at least 80% of their treatment (WHO, 2003).
The clinical control over the disease was based on the 
blood pressure readings. All patients with blood pressure 
values below 140 mmHg systolic and 90 mmHg diastolic 
were considered controlled (Koenigsfeld et al., 2015), 
even patients with comorbidities present pressure goal with 
values less than 130/80 mm Hg (Hypertension (SBC, 2010). 
For the purpose of this study, blood pressure before the 
intervention was calculated by averaging the measurements 
obtained during the first and second meetings. The pressure 
after the intervention was calculated by averaging the 
measurements obtained during the third visit.
Additional diseases mentioned by the patients 
were categorized using the International Statistical 
Classification of Diseases and Related Health Problems 
(ICD-10) (WHO, 2010).
The classification of medications used by the 
patients was performed by using the Anatomic Therapeutic 
Chemical (ATC) classification developed by the WHO 
(2015).
The data collected were entered into the EpiData 
3.1 software and were later analyzed using the EpiInfo 
6.0 and Statistical Package for Social Sciences (SPSS) 
19.0. The results were initially displayed descriptively; 
nominal variables were presented as absolute numbers and 
proportions, whereas numerical variables were presented 
as measures of central tendency and dispersion.
The Shapiro-Wilk test was initially used as a 
numerical means of assessing normality of the data for 
examining the influence of the pharmacotherapy review 
on adherence and clinical management of hypertension. 
The McNemar test was used to assess the influence of 
intervention upon categorical variables (proportion of 
adherent patients shown by the Morisky-Green test and 
proportion of self-reported adherence). Paired t-tests 
were used to assess numerical variables with normal 
distribution, whereas Wilcoxon test was used for numeric 
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FIGURE 2 - Review report delivered to patients in stage 2.
variables with non-normal distribution; p<0.05 was 
considered to be statistically significant. 
Ethical considerations
This project was designed in accordance with the 
recommendations of Resolution 196 of the Brazilian 
National Health Council. It was submitted to and 
approved by the Research Ethics Committee of University 
of Southern Santa Catarina under protocol number 
12.414.4.03.III.
RESULTS
The study included 40 patients, whose mean age 
was 58.0 (SD: 11.3) years, ranging from 30 to 79 years. 
Further information about sociodemographic variables 
and behavioral characteristics of participants is shown in 
Table I. 
Besides hypertension (HBP), which was a condition 
to participate in the study, the most common illnesses 
reported by patients were diabetes mellitus (8; 20.0%), 
dyslipidemia (8; 20.0%), and cardiovascular disease 
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(7; 17.5%). The classification of other health problems, 
according to the ICD-10 (WHO, 2010), is shown in Table II.
Overa l l ,  the  par t ic ipants  were  us ing  175 
pharmaceutical products. Table III shows the description 
of drugs, according to the ATC classification system 
(WHO, 2015), specifying the main anatomical groups 
(level 1) and the main therapeutic groups (level 2).
According to the ATC classification (WHO, 2015), 
most drugs belonged to the cardiovascular system (C) 
(101; 57.7%). Of these, drugs that acted on the renin-
angiotensin system were prevalent among the therapeutic 
group (40; 22.8%), of which losartan was the most 
commonly used (25; 47.5%).
The most frequently used psychoanaleptic and 
psycholeptic (anxiolytic) agents that act on the nervous 
system (N) (39; 22.3%) were fluoxetine and bromazepam, 
respectively. In this group of patients, the prevalence of 
clonazepam use was 22.5% (9). Although this medication 
is classified as an antiepileptic drug, patients used it to 
treat insomnia. Among the drugs that act on the digestive 
TABLE I - Profile of participant adherence to treatment through 
pharmacotherapy review
Variable n %
Gender 
     Male 
     Female
 
11 (27.5) 
29 (72.5)
Age a 
     Up to 59 years 
     60 years and above
 
20 (50.0) 
20 (50.0)
Education 
     Up to 8 years of schooling 
     9 years or more of schooling
 
29 (72.5) 
11 (27.5)
Physical activity 
     Yes 
     No
 
14 (35.0) 
26 (65.0)
Sodium intake control 
     Yes 
     No
 
34 (85.0) 
6 (15.0)
a Median. 
TABLE II - Health problems reported by patients, according to ICD-10 classification
Title CID-10 Disease categories n (%)
Diseases of the circulatory system
Hypertensive diseases 40 (100.0)
Ischemic heart disease 7 (17.5)
Cerebrovascular diseases 1 (2.5)
Endocrine, nutritional and metabolic diseases
Disorders of lipoprotein metabolism and 
other dyslipidemias 8 (20.0)
Diabetes Mellitus 8 (20.0)
Mental and behavioral disorders
Nervous system diseases 1 (2.5)
Neurotic stress-related and somatoform 
disorders 3 (7.5)
Mood (affective) disorders 4 (10.0)
Mental and behavioral disorders 1 (2.5)
Respiratory diseases
Other diseases of the upper respiratory 
tract 1 (2.5)
Lower respiratory tract diseases 2 (5.0)
Digestive system diseases Diseases of esophagus, stomach and duodenum 1 (2.5)
Diseases of the musculoskeletal system and connective tissue
Disorders of bone density and structure 2 (5.0)
Spinal disease (dorsopathy) 1 (2.5)
Arthritis  2 (5.0)
Rheumatism 3 (7.5)
Inflammatory polyarthritis 1 (2.5)
Non-inflammatory disorders of the genitourinary system Menopausal and perimenopausal disorders 1 (2.5)
Other inner ear disorders Labyrinthitis 2 (5.0)
Other thyroid problems Thyroid gland disorders 1 (2.5)
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TABLE III - Drugs used by patients, according to the ATC classification
Anatomical main group Therapeutic main group n (%)
A-Alimentary tract and metabolism 18 (10.2)
A02 – Drugs for acid related disorders 
A10 – Drugs used in diabetes 
A12 – Mineral supplements
3 (1.7) 
11 (6.3) 
4 (2.3)
B-Blood and blood forming organs 8 (4.6)
B01 – Antithrombotic agents 8 (4.6)
C-Cardiovascular system 101 (57.7)
C01 – Cardiac therapy 
C02 – Antihypertensive 
C03 – Diuretics  
C07 – Beta blocking agents 
C08 – Calcium channel blockers 
C09 – Agents acting on the renin-angiotensin system 
C10 – Lipid modifying agents
4 (2.3) 
1 (0.6) 
25 (14.2) 
13 (7.4) 
4 (2.3) 
40 (22.8) 
14 (8.0)
G- Genitourinary system and sex hormones 1 (0.6)
G03 - Sex hormones and modulators of the genital system 1(0.6)
H- Systemic hormonal preparations (excluding 
sex hormones and insulin)
2 (1.2)
H03 - Thyroid therapy 2 (1.2)
M- Musculoskeletal System 5 (2.8)
M01- Antiinflammatory and antirheumatic products 
M05- Drugs for treatment of bone diseases
4 (2.3) 
1(0.6)
N- Nervous System 39 (22.3)
N02- Analgesics  
N03- Antiepileptics  
N05- Psycholeptics (anxiolytics) 
N06- Psychoanaleptics
1 (0.6) 
9 (5.0) 
13(7.4) 
16 (9.0)
R- Respiratory System 1 (0.6)
R03- Drugs for obstructive airway diseases 1 (0.6)
Total 175 (100.0)
tract and metabolism (A) (18; 10.2%), those used for the 
treatment of diabetes mellitus, especially metformin, were 
the most frequently used drugs for 7 (17.5%) patients. 
Acetylsalicylic acid (aspirin) was the only drug acting in 
the blood and blood-forming organ (B) that was used by 
20% (8) of the patients.
Some cases of unusual doses found in this study 
included a sub-dose of glucosamine and chondroitin and a 
sub-dose of captopril. The concomitant use of medications 
from the same pharmacologic class was also identified in 
one case.
The number of drugs used by patients ranged from 
one to nine, having a mean of 4.4 (SD: 2.2) medications 
per patient. These figures remained unchanged after the 
interventions.
Table IV presents the results of the variables 
analyzed to assess the influence of the review of 
pharmacotherapy on the characteristics of treatment, 
adherence rate, and blood pressure control of the study 
participants.
Importantly, there was no significant difference 
between the blood pressure measurements between the 
Stage 1 and Stage 2, so that the average of the two values 
was regarded as before intervention.
Of the respondents, 33 (82.5%) were not able to keep 
the transcript of the routine initially described, requiring 
at least one intervention each to undertake the revision 
report. The most common interventions (30; 75.0%) were 
related to changing the interval between doses and possible 
drug-food interactions (13; 32.5%).
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During the last meeting, patients were asked 
about the place where they kept the intervention report. 
Seventeen (42.5%) of them kept near the drugs, nine 
(22.5%) used magnets to post on the refrigerator door, 
eight (20.0%) had saved elsewhere together with exams 
and prescriptions, and six (15.5%) did not remember 
where they had kept the report.
Furthermore, we investigated the perception of 
respondents regarding the role of intervention upon the 
adherence to treatment. The majority (87.5%) considered 
the intervention as a positive contribution to improve 
medication use.
DISCUSSION
The sociodemographic profile observed in this study 
was similar to that found in other studies on adherence to 
hypertension treatment (Trauthman et al., 2014; Santa-
Helena, Nemes, Neto-Eluf, 2008), mainly regarding low 
education and age group, which were cited as factors 
affecting adherence to therapy, since they were crucial in 
the understanding of the information received (Nair et al., 
2011; Vrijens et al., 2008; WHO, 2003).
Among the non-pharmacological measures, the 
most often cited by participants was the control of sodium 
intake. This control is positive, because sodium intake 
is directly related to increased blood pressure, which is 
corroborated by Pierin and colleagues, who evaluated 
hypertension control and associated factors (Pierin et al., 
2011). However, the present study did not investigate 
whether the non-pharmacological measures were adequate 
for the control of blood pressure levels.
The nosological profile of the participants was in line 
with other studies (Trauthman et al., 2014; Bastos-Barbosa 
et al., 2012; Acúrcio et al., 2009), since it was related 
mainly to other common problems such as metabolic 
syndrome, diabetes and dyslipidemia (SBC, 2010). 
As for the pharmacotherapeutic profile, since it was a 
group of hypertensive patients, most were poli-medicated 
and used different therapeutic classes for the management 
of health problems. However, there was a low prevalence 
use of antiplatelet drugs, such as acetylsalicylic acid, 
recommended by the 6th Arterial Hypertension Guideline 
(Sociedade Brasileira de Cardiologia, 2010). This finding 
may reflect a limitation of the study since medication 
reconciliation was not carried out through consultation of 
medical records. If they were not prescribed, the need for 
these products should be assessed, and interventions to 
improve prescribing should be made. When the drugs were 
evaluated according to their anatomical groups, they were 
similar to other studies (Trauthman et al., 2014; Acúrcio et 
al., 2009) that evaluated medication complexity prescribed 
for elderly people. 
The intervention performed in this study is 
contextualized within the pharmaceutical and clinical 
services and is part of the pharmacotherapy review 
(Leikola et al., 2012; Geurts et al., 2012; Holland et 
al., 2007). Drug administration schedule discussed 
here reflects the organization of the patients’ routine 
indicating the best schedule for medication management 
and addressing issues related to safety and effectiveness 
(Leikola et al., 2012).
Information contained in medical prescriptions, 
follow-up cards and patient’s report without consulting 
the medical records can generate outdated information and 
omission of prescribed medications. In Brazil, dispensing 
pharmacies do not have access to computerized patient 
records. Although they are not the most reliable sources of 
information, they are the only available reference.
All unusual doses of medications were clarified with 
TABLE IV - Influence of pharmacotherapy review upon the characteristics of treatment, medication adherence and blood pressure 
control of the study participants n=40
Variables Before intervention After intervention p-value
Adherent subjects 
Morisky-Green test - n (%) 
Self-report - n (%)
 
15 (37.5) 
28 (70.0)
 
30 (75.0) 
37 (92.5)
 
<0.001a 
0.004a
Reported adherence score -  –X (SD) 8.2 (1.7) 8.9 (1.0) <0.001b
Controlled blood pressure - n (%) 21 (52.5) 31 (77.5) 0.006 a
Systolic blood pressure reading -  –X (SD) 136.0 (22.1) 125.0 (26.3) <0.001 c
Diastolic blood pressure reading -  –X (SD) 84.5 (14.2) 80.0 (15.7) 0.002 b
Number of doses -  –X (SD) 5.6 (3.6) 5.9 (3.9) 0.039 b
Number of intakes -  –X (SD) 2.8 (1.1) 3.2 (1.3) 0.025 b
 –X  - mean; SD – standard deviation; a McNemar test, b Wilcoxon test; c Paired t test. 
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the patient prior to issuing the review report. The proposed 
report, therefore, presented ways to fit the medication 
regimen into the patients’ routines. For most patients, the 
report diverged from the way the drugs were taken. The 
reasons for this intervention were particularly related to 
the need to respect the intervals of drug administration, 
the number of doses, effectiveness of treatment (e.g., 
statins administered in a single dose and long before 
bedtime), or avoid food-drug interactions (e.g., captopril 
when associated with food). Such changes have also been 
made in the study by Silva and colleagues who evaluated 
the pharmaceutical care services to optimize therapeutic 
outcomes in hypertensive subjects (Silva et al., 2008).
The intervention performed increased significantly 
adherence rates among patients when assessed by both 
the self-reported adherence and the Morisky-Green 
test. These findings were in agreement with studies 
(Skowron, Polak, Brandys, 2011; Nobre, Ribeiro, 
Mion, 2010; Sociedade Brasileira de Cardiologia, 2010; 
Prado, Kupek, Mion, 2007; Lyra et al., 2007) showing 
that pharmaceutical interventions intended to increase 
motivation and adherence to treatment help improve 
medication adherence.
In a study conducted by Nobre, Ribeiro and Mion 
on blood pressure control in Brazil (Nobre, Ribeiro, 
Mion, 2010), the number of patients with controlled blood 
pressure was similar to that found in this study before the 
intervention. Analysis of blood pressure readings before 
and after the intervention revealed that pharmaceutical 
intervention improved control of blood pressure, which 
is in agreement with the 6th Brazilian Guidelines on 
Hypertension (Sociedade Brasileira de Cardiologia, 2010), 
meaning that adherence to treatment changes the disease 
control (Skowron, Polak, Brandys, 2011; Vrijens et al., 
2008; Silva et al., 2008). 
Moreover, interventions significantly increased the 
number of daily doses and the number of drug intakes per 
day. To a certain extent, interventions increased treatment 
complexity (Acúrcio et al., 2009). Thus, it is suggested 
that all medication schedules should be regularly prepared 
by prescribers, especially pharmacists. Preferably, this 
service must be redone at every change in treatment, even 
if temporarily. In this case, they should always be preceded 
by medication reconciliation (Geurts et al., 2012).
Effective and safe medication schedules should 
ideally be held from the beginning of treatment (Chemello 
et al., 2014), not as a means of correcting safety and 
effectiveness problems observed after the incorrect use. 
It is believed that once a patient develops a habit of using 
the medication incorrectly, it is more difficult to readapt 
to the correct use and avoid health risks.
This study did not aim to make economic analyzes 
such as those conducted by Obreli-Neto et al. (2015) 
and Correr et al. (2009), but those studies show that 
pharmaceutical services are financially viable for the 
prevention of harm to patients with chronic diseases. 
Recently, Houle et al. (2014) presented the costs of 
pharmacotherapy review services in different countries 
demonstrating costs from US$ 42.16 to 150.00 per 
encounter depending on the complexity of the case and the 
location of the service. In the same context, Chinthammit 
et al. (2015) asserted that the probability of avoiding 
a preventable adverse drug effect (ADE) is 0.93 (95% 
CI 0.91-0.95), and the cost of treating a preventable 
ADE is between US$ 116.87 and US$ 10,056.44. To 
these authors, the ADE can be the ineffective action of 
medicines.  From this information, even without a specific 
economic analysis, it is plausible to suppose that the 
medication review is cost-effective for the management 
of hypertension. However, news studied will be conducted 
for this purpose.
Limitations of this study included the fact that 
the source of information about medications used 
by patients was not controlled, and the influence of 
non-pharmacological measures was not investigated. 
Furthermore, even patients with comorbidities presented 
a pressure goal with values less than 140/90 mm Hg. 
Another limitation was related to data analysis, because 
we did not control several factors involved in blood 
pressure control beyond adherence, such as the choice of 
medicines and time of diagnosis. It was also not the aim of 
this study to analyze the inappropriate choice of therapy. 
However, even with these limitations, evidence was 
found to demonstrate the importance of pharmaceutical 
interventions in improving medication adherence and 
blood pressure control.
CONCLUSION
Review pharmacotherapy service developed in this 
study could significantly promote increased adherence 
to medication and blood pressure control, even if they 
increase the complexity of treatment, due to the larger 
number of drug doses and daily intakes.
In addition, the pharmacotherapy review can 
identify, prevent and resolve drug-related problems, 
minimizing incidents and reducing adverse effects. 
Further development of pharmacotherapy review 
is required to implement these services in community 
pharmacies. Nonetheless, there is a clear need for these 
services, due to the outcome of morbidity and mortality 
rates related to hypertension and other chronic diseases.
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